Please login to the form below

Not currently logged in
Email:
Password:

Novartis in health technology assessment trial with NICE

Novartis is collaborating with the UK's medicines agency, the National Institute of Health and Clinical Excellence on the joint design of a late-stage clinical trial to assess efficacy and health economics of a new drug

According to the UK newspaper The Financial Times, Swiss-headquartered Novartis has collaborated with the UK's medicines agency, the National Institute of Health and Clinical Excellence (NICE) on the joint design of a late-stage clinical trial.

According to the 17 December article, NICE will charge a fee for informing Novartis which criteria will form the basis of its decision to advise the NHS whether to buy the medicine once it is launched.

In an interview with the FT, Joe Jimenez, Novartis' head of pharmaceuticals, said: "This is about identifying the impact of the drug and the evidence of impact. Input at an early stage gives us the evidence to speed our drug to market. We're looking at more innovative ways to stand behind our drugs."

In November 2007, Novartis consulted with NICE on the design of the phase III trial for the drug, which is currently named Novartis 001.

According to the FT, the results of the trial are expected within a year.

19th December 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics